Skip to main content

Table 1 Baseline Demographic and Clinical Characteristics

From: Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

  Original cohort Propensity-score matching cohort
Second-Line Treatment Afatinib
(n = 19)
Chemotherapy
(n = 89)
p-value Afatinib
(n = 19)
Chemotherapy
(n = 19)
p-value
Age, y (IQR) 71 (63–82) 67 (61–74) 0.107 71 (63–82) 66 (60–74) 0.144
Male, n (%) 14 (73.7) 73 (82.0) 0.404 14 (73.7) 16 (84.2) 0.426
Smoking status, n (%)    0.875    0.721
 Never smoker 5 (26.3) 25 (28.1)   5 (26.3) 6 (31.6)  
 Ex-smoker 1 (5.3) 21(23.6)   1 (5.3) 3 (15.8)  
 Current smoker 13 (68.4) 44 (49.4)   13 (68.4) 10 (52.6)  
First-line chemotherapy, n (%)    0.118    0.174
 Platinum-based 11 (57.9) 71 (79.8)   11 (57.9) 15 (78.9)  
 Not platinum-based 8 (42.1) 18 (20.2)   8 (42.1) 4 (21.1)  
Initial clinical stage, n (%)    0.331    0.283
 IIIB/C 7 (36.8) 24 (27.0)   7 (36.8) 4 (21.1)  
IV 12 (63.2) 65 (73.0)   12 (63.2) 15 (78.9)  
Baseline ECOG PS    0.135    0.221
 0/1 12 (63.2) 76 (85.4)   12 (63.2) 16 (84.2)  
  ≥ 2 7 (36.8) 13 (14.6)   7 (36.8) 3 (15.8)  
EGFR status, n (%)    0.577    0.560
 Wild-type 7 (36.8) 39 (43.8)   7 (36.8) 5 (26.3)  
 Not tested 12 (63.2) 50 (56.2)   12 (63.2) 14 (73.7)  
PD-L1 expression level, n (%)    0.278    0.530
  < 1% 5 (26.3) 13 (14.6)   5 (26.3) 2 (10.5)  
 1–49% 2 (10.5) 27 (30.3)   2 (10.5) 3 (15.8)  
  > 50% 2 (10.5) 10 (11.2)   2 (10.5) 1 (5.3)  
 Not tested 10 (52.6) 39 (43.8)   10 (52.6) 13 (68.4)  
Sites of metastatic disease, n (%)       
 Liver 0 (0) 10 (11.2) 0.125 0 (0) 1 (5.3) 0.311
 Contralateral lung nodule 7 (36.8) 25 (28.1) 0.448 7 (36.8) 3 (15.8) 0.141
 Bone 3 (15.8) 25 (28.1) 0.267 3 (15.8) 5 (26.3) 0.426
 Pleural (nodules, effusion) 2 (10.5) 15 (16.9) 0.641 2 (10.5) 5 (26.3) 0.209
 Brain 6 (31.6) 12 (13.5) 0.055 6 (31.6) 4 (21.1) 0.521
 Other 0 (0) 7 (7.9) 0.718 0 (0) 3 (15.8) 0.107
Comorbidity, n (%)
 Hypertension 4 (21.1) 42 (47.2) 0.054 4 (21.1) 9 (47.4) 0.087
 Chronic kidney disease 0 (0) 3 (3.4) 0.417 0 (0) 1 (5.3) 0.311
 Diabetes mellitus 4 (21.1) 22 (24.7) 0.734 4 (21.1) 5 (26.3) 0.703
 Hepatic disease 0 (0) 9 (10.1) 0.148 0 (0) 2 (10.5) 0.214
 Pulmonary disease 4 (21.1) 25 (28.1) 0.734 4 (21.1) 2 (10.5) 0.374
  1. IQR interquartile range; ECOG PS Eastern Cooperative Oncology Group performance status; EGFR epidermal growth factor receptor; PD-L1 programmed cell death protein 1